Publication:
Enzymatic debridement with bromelain and development of bacteremia in burn injuries: A retrospective cohort study.

cris.virtualsource.author-orcidc6752d14-6930-407c-bcb9-e0fb392a14aa
datacite.rightsopen.access
dc.contributor.authorDeplazes, Barla C
dc.contributor.authorHofmaenner, Daniel A
dc.contributor.authorScheier, Thomas C
dc.contributor.authorEpprecht, Jana
dc.contributor.authorMayer, Michelle
dc.contributor.authorSchweizer, Tiziano A
dc.contributor.authorBuehler, Philipp K
dc.contributor.authorFrey, Pascal Marcel
dc.contributor.authorBrugger, Silvio D
dc.date.accessioned2024-10-26T16:55:59Z
dc.date.available2024-10-26T16:55:59Z
dc.date.issued2024-03
dc.description.abstractBACKGROUND Debridement is crucial for effective wound management in patients with severe burn injuries, and bromelain, a proteolytic enzyme from pineapple stems, has emerged as a promising alternative for surgery. However, potential links of bromelain use to fever and sepsis have raised some concerns. Given the uncertainty as to whether this was caused by infection or other inflammatory sources, we aimed to investigate if the use of topical bromelain was associated with bacteremia. METHODS This single-centre retrospective cohort study included critically ill adult patients with severe burn injuries hospitalised at the Burn Center of the University Hospital Zurich between January 2017 and December 2021. Data were collected from two in-hospital electronic medical records databases. Our primary outcome, the association between topical bromelain treatment and the development of bacteremia, was investigated using a competing risk regression model, taking into account the competing risk of death. As a secondary outcome, the relationship between bromelain treatment and overall ICU mortality was examined using a Cox proportional hazards model. RESULTS The study included 269 patients with a median age of 50 years and median burnt total body surface area of 19%. A first bacteremia occurred in 61 patients (23%) after a median time of 6 days. Bromelain treatment was given to 83 (31%) of patients, with 22 (27%) of these developing bacteremia. In the fully adjusted competing risk regression model, no evidence for an association between bromelain treatment and bacteremia was found (SHR 0.79, 95%CI 0.42-1.48, p = 0.47). During hospital stay, 40 (15%) of patients died. There was no significant difference in mortality between patients treated with bromelain and those who were not (HR 0.55, 95%CI 0.26-1.20, p = 0.14). Among the five multidrug-resistant (MDR) pathogens identified, three were found in patients with bromelain treatment. CONCLUSION Our study did not confirm an association between topical bromelain and bacteremia in patients with severe burn injuries. This finding can inform evidence-based practices by addressing concerns about potential risks of bromelain use, contributing to the development of more effective and safe burn wound management strategies.
dc.description.numberOfPages8
dc.description.sponsorshipUniversitätsklinik für Allgemeine Innere Medizin
dc.identifier.doi10.48350/191328
dc.identifier.pmid38182450
dc.identifier.publisherDOI10.1016/j.burns.2023.12.005
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/173149
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofBurns
dc.relation.issn0305-4179
dc.relation.organizationDCD5A442C058E17DE0405C82790C4DE2
dc.subjectBloodstream infection Bromelain treatment Burns patients
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleEnzymatic debridement with bromelain and development of bacteremia in burn injuries: A retrospective cohort study.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage412
oaire.citation.issue2
oaire.citation.startPage405
oaire.citation.volume50
oairecerif.author.affiliationUniversitätsklinik für Allgemeine Innere Medizin
unibe.contributor.equalauthtrue
unibe.contributor.equalauthtrue
unibe.contributor.equalauthtrue
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2024-01-12 04:55:35
unibe.description.ispublishedpub
unibe.eprints.legacyId191328
unibe.journal.abbrevTitleBURNS
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
1-s2.0-S0305417923002607-main.pdf
Size:
1.19 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by/4.0
Content:
published

Collections